Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool June 10, 2004 Alyce Lomax	Summer Starts at CVS The drugstore company releases same-store sales results on the cusp of its Eckerd acquisition.
The Motley Fool July 6, 2004 Alyce Lomax	Not Ready for Rite Aid Can the drugstore chain hold a candle to the competition? Its shares are trading at 22 times forward earnings, making it a seemingly less-than-advantageous time to place a bet on them.
The Motley Fool June 2, 2004 Alyce Lomax	Walgreen's Mellow May Will the drugstore chain get a taste of its own medicine?
The Motley Fool March 24, 2004 Dave Marino-Nachison	Eking Out an Eckerd Deal Investors are still waiting for a new leader to be crowned in the U.S. drugstore business.
The Motley Fool March 22, 2004 Alyce Lomax	Walgreen's Green Quarter Investors take an earnings miss to heart. But the future looks good.
The Motley Fool August 4, 2004 Phil Wohl	CVS's Prescription for Competition The national drugstore chain is looking to take advantage of increased size.
The Motley Fool April 5, 2004 Dave Marino-Nachison	Finally, Eckerd Sells J.C. Penney's drugstore operation will be split between CVS and Jean Coutu.
The Motley Fool January 5, 2004 Jeff Hwang	Prescriptions Boost Walgreen Earnings and sales bumped by early flu season and improved non-pharmacy sales.
The Motley Fool March 5, 2004 Dave Marino-Nachison	Longs Coming Up Short Investors who bid on a Longs buyout haven't been rewarded in recent months.
The Motley Fool July 6, 2004 Steven Mallas	Walgreen's Sunny Sales The retail pharmacy has a resplendently ruddy June, with comp sales increasing more than 10%.
The Motley Fool August 3, 2004 Rich Duprey	Penney Kicks Drugstore Habit The retailer has completed its sale of Eckerd Drugs to focus on selling clothes. While investors can and should enjoy Penney's current clear-eyed plans, they ought to keep a watchful eye out for any relapse.
The Motley Fool May 5, 2004 Mike Cianciolo	CVS Prescribes Growth The soon-to-be leader of the drugstore market had a spectacular first quarter as a result of improved sales and margins, and CVS doesn't appear to be showing any signs of slowing down either, as the company continues to expand its business in both traditional and creative ways.
BusinessWeek February 23, 2004 Robert Barker	What's That Smell At Duane Reade? Will Duane Reade, New York City's dominant drugstore, chain be bought out by Oak Hill Capital Partners?
The Motley Fool July 7, 2004 Steven Mallas	CVS's Bright Picture Send CVS your digital photos over the Net, pick them up the next day. While competitors are sure to follow suit, this still shows how intellegent and creative this drugstore blue chip can be.
The Motley Fool May 9, 2005 Timothy M. Otte	Flu Means All's Well for CVS Strong comp sales and benefits from the Eckerd acquisition drive CVS to a solid first quarter. Investors, take note.
The Motley Fool February 12, 2004 Dave Marino-Nachison	CVS Bags Big 2003 A strong year for the drugstore giant has spilled into January.
The Motley Fool September 7, 2004 Seth Jayson	Rejecting Rite Aid Shares of the drugstore chain droped 13%, and may prove to be a bargain if this is indeed a temporary slowdown and management can deliver more robust growth.
The Motley Fool June 25, 2004 Steven Mallas	Rite Aid in the Shadows The first quarter for Rite Aid, the pharmaceutical retailer, shows a profit, but is it time to add this stock to your portfolio?
The Motley Fool March 23, 2011 Andrew Bond	What More Can You Ask of Walgreen? A sell-off in shares of Walgreen provides a buying opportunity for investors who want in on a best-of-breed company at a discount.
The Motley Fool July 5, 2005 Alyce Lomax	Business As Usual at Walgreen Walgreen's same-store sales for June certainly don't disappoint. Investors might question whether the retail pharmacy can keep up the great work.
The Motley Fool June 11, 2007 Mike Cianciolo	Rite Aid's Generic Sales The drugstore chain gradually increases sales, and catches up to the big boys in one way. Investors, take note.
The Motley Fool September 24, 2004 Seth Jayson	Kick This Drug Habit Rite Aid offers slow sales and minuscule shareholder rewards.
The Motley Fool February 2, 2005 Alyce Lomax	CVS's Shot in the Arm Buying the Eckerd drugstore chain from J.C. Penney was apparently a good move for CVS. It continues to benefit from the purchase, reporting positive earnings and beating analysts' expectations by a penny.
The Motley Fool January 4, 2008 Timothy M. Otte	Drugstore Sales Droop in December The three major drugstore chains, Walgreen, CVS, and Rite Aid, all report soft sales for December.
The Motley Fool April 9, 2007 Mike Cianciolo	CVS: Continued Vigorous Sales The drugstore chain grows sales and itself in March. Investors, take note.
The Motley Fool March 9, 2004 Alyce Lomax	February Frenzy at CVS, Rite Aid The flu season's early end hasn't stopped drugstore retailers.
The Motley Fool July 6, 2007 Timothy M. Otte	Drugstore Sales Remain Healthy The big four drugstore chains report higher comparable sales in June. Walgreen... CVS... Rite Aid... Long's...
The Motley Fool September 22, 2006 Ryan Fuhrmann	More in Store at Rite Aid? The retail pharmacy posted strong second-quarter sales, and an acquisition could help long-term results. Investors, take note.
The Motley Fool June 29, 2007 Ryan Fuhrmann	Rite Aid's Recent Remedy Will increased market clout lead the drugstore operator to new highs? Investors, take note.
The Motley Fool June 21, 2004 Seth Jayson	Walgreen's Fine Follow-Up It's another solid quarter for America's soon-to-be No. 2 drugstore.
The Motley Fool January 13, 2004 Alyce Lomax	CVS Fever Drug stores benefit from the flu bug, but for how much longer?
The Motley Fool February 26, 2004 Alyce Lomax	Pinching J.C. Penney Eckerd is still a pain, but will Penney fly when it's on its own? Penney's reported a net loss of $1.07 billion, or $3.42 per share, as compared to earnings of $202 million, or $0.68 per share, in the same quarter last year.
The Motley Fool November 10, 2004 Dave Marino-Nachison	Investors Adjusting to Larger CVS The drugstore company's chains have done nothing but rise since the Eckerd buy. Investors have pulled the company's shares steadily upward since the merger closed.
The Motley Fool March 28, 2005 Alyce Lomax	A Cool Quarter for Walgreen Are second-quarter earnings putting a damper on Walgreen?
The Motley Fool August 15, 2005 Bobby Shethia	Walgreen's Prescription for Success The drugstore chain's smart and steady growth makes it a good choice for investors.
The Motley Fool May 18, 2004 Seth Jayson	Perky Days for J.C. Penney This cornerstone of the American mall is outrunning its rivals.
The Motley Fool April 8, 2004 Seth Jayson	Rite Aid Wrings Out Profits Net store closings and comps increases bring black ink to the pharmacy's bottom line.
The Motley Fool March 6, 2008 Timothy M. Otte	Longs Drugs Has a Nice Niche West Coast regional drugstore chain scores solid fourth quarter.
The Motley Fool April 4, 2007 Timothy M. Otte	Walgreen's Comp Machine The drugstore operator steams through March with 8% comparable sales growth. The stock trades at a P/E of 24 times trailing-12-month earnings, about one-third higher than the average of all S&P 500 companies.
The Motley Fool September 27, 2004 Phil Wohl	Walgreen: Prescription for Success The leading drugstore retailer is leveraging prescription sales to produce record results. Fourth-quarter earnings grew to $0.32 per share, which was an 18% improvement over last year's $0.27.
The Motley Fool September 25, 2009 Chris Jones	The First Symptom of Health-Care Troubles? Rite Aid's problems imply bad news for consumers and the health-care system.
The Motley Fool October 5, 2007 Timothy M. Otte	CVS: Consistently Very Solid The drugstore giant scores a consistent sales increase in September, as it begins to capitalize on synergies from its CareMark acquisition.
The Motley Fool March 26, 2010 Cathy Applefeld Olson	Can CVS Caremark Win the Drug Wars? Now that health-care legislation has been signed into law, it's a perfect time to give the country's largest drugstore chain a checkup.
The Motley Fool September 14, 2006 Ryan Fuhrmann	Playing Defense With the Drugstore Industry Retail pharmacy August sales trends help investors discern the leader in this appealing sector.
The Motley Fool January 4, 2005 Seth Jayson	Rite Aid Still Needs First Aid Sales keep slacking for this tough turnaround. This doesn't mean investors should necessarily jump ship.
The Motley Fool February 4, 2005 Steven Mallas	Walgreen's Wonderful Comps This drugstore chain doesn't need any medical attention. January comps prove it.
The Motley Fool September 27, 2007 Ryan Fuhrmann	Rite Aid Looks a Little Peaked Bigger doesn't necessarily mean better for the drugstore retailer; it has quite a bit of work to do to convince investors it can successfully manage the empire that it has acquired.
The Motley Fool December 11, 2006 Matthew Crews	Rite Aid: Comps Mean Competition The pharmacy chain reported positive same-store results for November. Investors, take note.
The Motley Fool November 9, 2005 Steven Mallas	CVS Needs Rx for Cash The drugstore chain has the prescription for earnings growth, but investors need to keep an eye on free cash flow.
The Motley Fool July 6, 2007 Mike Cianciolo	Walgreen: The New Deal Maker Walgreen announces its latest acquisition as it tries to keep pace with the competition. Investors, take note.